RPS6KA1 and breast carcinoma: The clinical value of phospho-p90RSK was further tested in locally advanced breast cancer patients who underwent neoadjuvant systemic chemotherapy which is a valuable platform to test the in vivo chemotherapy-sensitivity [11].